Vivos Therapeutics (VVOS) Debt Ratio (2019 - 2026)

Vivos Therapeutics (VVOS) reported Debt Ratio of 0.31 for Q1 2026, down 12.14% quarter-over-quarter from 0.35 in Q4 2025.

Vivos Therapeutics (VVOS) Debt Ratio (2019 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has 5 years of Debt Ratio data on file, last reported at 0.31 in Q1 2026.

Debt Ratio for Q1 2026 came in at 0.31, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.31 (changed N/A YoY), and the FY2025 annual result was 0.35, changed N/A from the prior year.
Debt Ratio slipped to 0.31 in Q1 2026 per VVOS's latest filing, from 0.35 in the prior quarter.
Over five years, Debt Ratio peaked at 0.35 in Q4 2025 and troughed at 0.3 in Q2 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.31
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.32
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.31
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.25
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.04
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.30
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.27
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.18
10	Vivos Therapeutics	7.39 Mn	5.16 Mn	3.06 Mn	0.31

Historic Data

Download Data

Date	Value
Mar 31, 2026	0.31
Dec 31, 2025	0.35
Sep 30, 2025	0.34
Jun 30, 2025	0.30
Dec 31, 2021	0.04
Sep 30, 2021	0.03
Jun 30, 2021	0.03
Mar 31, 2021	0.06
Dec 31, 2020	0.05
Dec 31, 2019	0.49